Commentary
Video
Author(s):
Joyce A. O’Shaughnessy, MD, and Neil M. Iyengar, MD, discuss the various management strategies for treatment of patients with advanced or metastatic HER2-positive breast cancer.
Lasofoxifene Aims to Amplify Efficacy of Abemaciclib in ESR1-Mutated ER+/HER2– Metastatic Breast Cancer
Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress
Postoperative Radiation Therapy Improves HRQOL, Safety in Early-Stage HR+/HER2– Breast Cancer
Park and Graff Explore the Evolving Role of CDK4/6 Inhibitors in Metastatic Breast Cancer
Elacestrant Improves Real-World Time to Next Treatment or Treatment Discontinuation in ESR1+ HR+/HER2– Breast Cancer
The OncFive: Top Oncology Articles for the Week of 12/8
Zongertinib Elicits Durable Responses in Pretreated Advanced HER2-Mutant NSCLC
Lenvatinib Shows Efficacy in Advanced HCC Post-Progression on Atezolizumab/Bevacizumab
Sacituzumab Govitecan Does Not Significantly Improve OS in Pretreated Urothelial Carcinoma
Active Monitoring Is Noninferior to Guideline Concordant Care in Low-Risk DCIS